iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
NEW HCV DRUGS Development
 
 
  ......from Jules:Epclusa was just approved, Zepatier approved earlier this year. Abbvie new double next generation ABT493+530 is under FDA review; gilead's new triple with new protease inhibitor is in later development stages; Merck's triple with nucleoside + next generation NS5A inhibitor + protease in development; J&J's triple with nucleoside & new NS%a inhibitor in phase 2 developmentrecentlyreported phase 2 new data -
 
Special EASL: Short duration treatment with AL-335 and odalasvir (ODV), with or without simeprevir (SMV), in treatment naïve patients with hepatitis C virus (HCV) genotype (GT) 1 infection - (09/26/16)
 
Special EASL: Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen's Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV - (09/26/16)
 
New HCV Drugs - Helicase Inhibitor - Cocrystal Pharma - (09/07/16)
 
Updated AASLD/IDSA HCV Guidelines - (09/19/16)
 
Trek's HCV DAAs - MIV-802 / TD-6450 - (09/02/16)......Trek Therapeutics buys rights to
 
Medivir's hep C candidate MIV-802 - (09/02/16)
 
HCV Resistance, DAA Failures, and Other difficult situations - Excerpts - (09/02/16)
 

HCV1

HCV2

  
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org